Q-omics provides the consensus-scored TRIM25 profile across patient tissues and cancer cell-line models. TRIM25 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TRIM25 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TRIM25 protein abundance shows 25,480 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight CESC, LIHC, and CCRCC as cancer lineages where TRIM25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM25 survival associations across molecular data types. TRIM25 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM25 RNA expression–survival associations across cancer types. High TRIM25 expression shows unfavorable associations in CESC, LIHC, ACC, KIRP and KIRC, but favorable associations in STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TRIM25 RNA expression.
This table summarizes TRIM25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM25 shows lower tumor expression in LUAD, THCA, BRCA and KICH and higher tumor expression in LIHC and STAD. The LIHC box plot shows higher TRIM25 RNA expression in tumor versus normal tissue (log2 FC = +1.553, t-test p < 0.001).
This table shows molecular features associated with TRIM25 in patient tissues and cancer cell lines. In patient samples, TRIM25 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
